2016 will see Pfizer continue to cling to first place in the top ten pharma list, but Merck & Co. and Novartis will not be far behind.

The biotechnology markets in the United States, Europe, and Canada, and Australia reached aggregate profitability in 2009, according to Ernst & Young.

The US Food and Drug Administration sent a letter to trade associations of manufacturers, wholesalers, and pharmacies to recommend procedures for preventing and responding to the theft of regulated products.

The year 2016 will see Pfizer barely continue to cling to first place on the Top 10 pharma list, with Merck & Co. and Novartis not far behind.

McNeil Consumer Healthcare is voluntarily recalling all lots that have not yet expired of certain over-the-counter children's and infants' liquid products.

European Parliament Approves Proposals On Falsified Medicines and Pharmacovigilance; And More.

FDA Approves AstraZeneca's and Pozen's Vimovo; Merck Announces Management Changes; And More.

Vetter has signed a preferred partnership with Sentry BioPharma Services whereby Vetter will fill early-stage, high-value biopharmaceuticals at its Chicago facility and Sentry will label, package and ship the clinical supplies from its site in Indianapolis.

Defining the Next Five Years.

The growth of Brazil's generic-drug market is on a fast track, but what are the projections for the sector's future?

A book helps statistics novices prepare to comply with the US Food and Drug Administration's draft guidance on process validation.

A Pharma Business Imperative.

Agreement on standards for excipient qualification, development, and fair pricing is underway.

When vessels, seals, and cooling units go haywire, operators must get in the mix.

The author proposes techniques, based on Six Sigma methods, for monitoring such processes to discover their airflow patterns and reduce opportunities for spillage.This article is part of PharmTech's supplement "Solid Dosage and Excipients 2010."

Over the last few months, we have been publishing a series of special features, which have sought to provide you with an overall view of current challenges, innovations and trends in niche pockets of the pharmaceutical industry.

A new automated factory in Boston (MA, USA) has been developed that uses non-genetically modified green plants to quickly produce large quantities of vaccines and therapeutics.

The European Medicines Agency published a summary report that includes suggestions for improving the current processes for evaluating benefit-risk.

FDA made available a draft guidance that would expand the information disclosed about conflict-of-interest waivers.

Charles River Acquires WuXi AppTec; Amgen Appoints President and COO; and More.

Genzyme provided an update on its manufacturing operations following the issuance of a draft consent decree by FDA regarding the company's Allston Landing, Massachusetts, manufacturing plant.

FDA Issues Warning Letter To Pfizer; And More.

The US Pharmacopeial Convention recently held its convention in Washington, DC.

AstraZeneca has finalized its agreement with US federal and state entities, under which it will pay $520 million to resolve allegations that it marketed the anti-psychotic drug Seroquel for off-label uses.

An evaluation conducted by Ernst & Young assessing the effectiveness and efficiency of the European Medicines Agency has largely praised the agency; however, a number of strategic and operational recommendations for further improvements have also been made.

Despite pharma's upcoming peak years of patent expiries and the threat of generic competition, growth during the next 5 years is expected to be strong with the global market for pharmaceuticals forecast to reach more than $1 trillion by 2014, according to IMS Health.

The Society of Chemical Manufacturers and Affiliates is raising concerns over a recently introduced bill in the US Senate, which seeks to reform the Toxic Substances Control Act.

INTERPHEX 2010 will take place this week at the Jacob K. Javits Center in New York.